GALMED PHARMACEUTICALS LTD (GLMD) Stock News

NASDAQ:GLMD - Nasdaq - IL0011313900 - Common Stock - Currency: USD

1.83 -0.5 (-21.46%)

After market: 1.9 +0.07 (+3.83%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

GLMD Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: RGC SMLR IRD APVO ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

2 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

3 months ago - By: Benzinga - Mentions: PLUG ROP GRPN TARA ...

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook

a year ago - By: InvestorPlace

GLMD Stock Earnings: Galmed Pharmaceuticals Reported Results for Q1 2024

3 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

3 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

3 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

3 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

4 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

4 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

10 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

10 months ago - By: FN Media Group LLC - Mentions: ONCY ONC.CA NVS MRK ...

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

a year ago - By: InvestorPlace - Mentions: MRIN MSFT ICCT NA ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

a year ago - By: InvestorPlace - Mentions: SLNA TCON

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024

a year ago - By: InvestorPlace

GLMD Stock Earnings: Galmed Pharmaceuticals Misses EPS for Q4 2023